FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591294588> ?p ?o ?g. }

• W2591294588 endingPage "219" @default.
• W2591294588 startingPage "204" @default.
• W2591294588 abstract "One of the hallmarks of cancer consists in the ability of tumor cells to divide indefinitely, and to maintain stable telomere lengths throughout the activation of specific telomere maintenance mechanisms (TMM). Therefore in the last fifteen years, researchers proposed to target telomerase or telomeric structure in order to block limitless replicative potential of cancer cells providing a fascinating strategy for a broad-spectrum cancer therapy. In the present review, we report in vitro and in vivo evidence regarding the use of chemical agents targeting both telomerase or telomere structure and showing promising antitumor effects when used in combination with ionizing radiation (IR). RNA interference, antisense oligonucleotides (e.g., GRN163L), non-nucleoside inhibitors (e.g., BIBR1532) and nucleoside analogs (e.g., AZT) represent some of the most potent strategies to inhibit telomerase activity used in combination with IR. Furthermore, radiosensitizing effects were demonstrated also for agents acting directly on the telomeric structure such as G4-ligands (e.g., RHPS4 and Telomestatin) or telomeric-oligos (T-oligos). To date, some of these compounds are under clinical evaluation (e.g., GRN163L and KML001). Advantages of Telomere/Telomerase Targeting Compounds (T/TTCs) coupled with radiotherapy may be relevant in the treatment of radioresistant tumors and in the development of new optimized treatment plans with reduced dose adsorbed by patients and consequent attenuation of short- end long-term side effects. Pros and cons of possible future applications in cancer therapy based on the combination of T/TCCs and radiation treatment are discussed." @default.
• W2591294588 created "2017-03-03" @default.
• W2591294588 creator A5008172943 @default.
• W2591294588 creator A5014145933 @default.
• W2591294588 creator A5014576319 @default.
• W2591294588 creator A5026124245 @default.
• W2591294588 date "2017-07-01" @default.
• W2591294588 modified "2023-10-12" @default.
• W2591294588 title "Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models" @default.
• W2591294588 cites W1517051009 @default.
• W2591294588 cites W1538980175 @default.
• W2591294588 cites W1540774389 @default.
• W2591294588 cites W1541877559 @default.
• W2591294588 cites W1543500873 @default.
• W2591294588 cites W1546643851 @default.
• W2591294588 cites W1585136919 @default.
• W2591294588 cites W1593021735 @default.
• W2591294588 cites W1608381171 @default.
• W2591294588 cites W1700797585 @default.
• W2591294588 cites W1878726100 @default.
• W2591294588 cites W1914649288 @default.
• W2591294588 cites W1919425358 @default.
• W2591294588 cites W1946594578 @default.
• W2591294588 cites W1963554650 @default.
• W2591294588 cites W1964151664 @default.
• W2591294588 cites W1965019589 @default.
• W2591294588 cites W1965336678 @default.
• W2591294588 cites W1965736220 @default.
• W2591294588 cites W1966549638 @default.
• W2591294588 cites W1966888005 @default.
• W2591294588 cites W1969782880 @default.
• W2591294588 cites W1970891016 @default.
• W2591294588 cites W1973577066 @default.
• W2591294588 cites W1974027105 @default.
• W2591294588 cites W1976778369 @default.
• W2591294588 cites W1977476599 @default.
• W2591294588 cites W1978518024 @default.
• W2591294588 cites W1978957025 @default.
• W2591294588 cites W1979708010 @default.
• W2591294588 cites W1980807374 @default.
• W2591294588 cites W1981475962 @default.
• W2591294588 cites W1982199027 @default.
• W2591294588 cites W1983138170 @default.
• W2591294588 cites W1983253512 @default.
• W2591294588 cites W1983673827 @default.
• W2591294588 cites W1984376253 @default.
• W2591294588 cites W1985964699 @default.
• W2591294588 cites W1986615467 @default.
• W2591294588 cites W1987643363 @default.
• W2591294588 cites W1989054568 @default.
• W2591294588 cites W1989413383 @default.
• W2591294588 cites W1990294201 @default.
• W2591294588 cites W1992158077 @default.
• W2591294588 cites W1993469796 @default.
• W2591294588 cites W1994017228 @default.
• W2591294588 cites W1996517555 @default.
• W2591294588 cites W1997338093 @default.
• W2591294588 cites W1997963513 @default.
• W2591294588 cites W1998661629 @default.
• W2591294588 cites W1998758780 @default.
• W2591294588 cites W1998772582 @default.
• W2591294588 cites W2005683083 @default.
• W2591294588 cites W2006606296 @default.
• W2591294588 cites W2007888447 @default.
• W2591294588 cites W2008815082 @default.
• W2591294588 cites W2010964636 @default.
• W2591294588 cites W2012002712 @default.
• W2591294588 cites W2012726998 @default.
• W2591294588 cites W2013752531 @default.
• W2591294588 cites W2013971815 @default.
• W2591294588 cites W2014013625 @default.
• W2591294588 cites W2014324433 @default.
• W2591294588 cites W2014482493 @default.
• W2591294588 cites W2015958589 @default.
• W2591294588 cites W2016199934 @default.
• W2591294588 cites W2017933374 @default.
• W2591294588 cites W2018598852 @default.
• W2591294588 cites W2021191052 @default.
• W2591294588 cites W2022013301 @default.
• W2591294588 cites W2022507419 @default.
• W2591294588 cites W2025535465 @default.
• W2591294588 cites W2027330624 @default.
• W2591294588 cites W2030976397 @default.
• W2591294588 cites W2031575431 @default.
• W2591294588 cites W2031786121 @default.
• W2591294588 cites W2032407757 @default.
• W2591294588 cites W2032745254 @default.
• W2591294588 cites W2033203283 @default.
• W2591294588 cites W2035552696 @default.
• W2591294588 cites W2037086740 @default.
• W2591294588 cites W2038861500 @default.
• W2591294588 cites W2038982713 @default.
• W2591294588 cites W2044126891 @default.
• W2591294588 cites W2044219549 @default.
• W2591294588 cites W2045125264 @default.
• W2591294588 cites W2045660156 @default.
• W2591294588 cites W2046461941 @default.
• W2591294588 cites W2047582165 @default.

• next